These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 17565982)
1. A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. Eavri R; Lorberboum-Galski H J Biol Chem; 2007 Aug; 282(32):23402-9. PubMed ID: 17565982 [TBL] [Abstract][Full Text] [Related]
2. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Oh HJ; Park ES; Kang S; Jo I; Jung SC Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195 [TBL] [Abstract][Full Text] [Related]
3. Trends in enzyme therapy for phenylketonuria. Kim W; Erlandsen H; Surendran S; Stevens RC; Gamez A; Michols-Matalon K; Tyring SK; Matalon R Mol Ther; 2004 Aug; 10(2):220-4. PubMed ID: 15294168 [TBL] [Abstract][Full Text] [Related]
4. Functional Characterization of Novel Phenylalanine Hydroxylase p.Gln226Lys Mutation Revealed Its Non-responsiveness to Tetrahydrobiopterin Treatment in Hepatoma Cellular Model. Klaassen K; Djordjevic M; Skakic A; Desviat LR; Pavlovic S; Perez B; Stojiljkovic M Biochem Genet; 2018 Oct; 56(5):533-541. PubMed ID: 29654578 [TBL] [Abstract][Full Text] [Related]
5. PKU mutation G46S is associated with increased aggregation and degradation of the phenylalanine hydroxylase enzyme. Eiken HG; Knappskog PM; Apold J; Flatmark T Hum Mutat; 1996; 7(3):228-38. PubMed ID: 8829656 [TBL] [Abstract][Full Text] [Related]
6. Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Gámez A; Wang L; Straub M; Patch MG; Stevens RC Mol Ther; 2004 Jan; 9(1):124-9. PubMed ID: 14741785 [TBL] [Abstract][Full Text] [Related]
7. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice. Harding CO; Neff M; Jones K; Wild K; Wolff JA J Gene Med; 2003 Nov; 5(11):984-93. PubMed ID: 14601136 [TBL] [Abstract][Full Text] [Related]
8. Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice. Winn SR; Dudley S; Scherer T; Rimann N; Thöny B; Boutros S; Krenik D; Raber J; Harding CO Mol Genet Metab; 2022 May; 136(1):46-64. PubMed ID: 35339387 [TBL] [Abstract][Full Text] [Related]
9. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Ding Z; Georgiev P; Thöny B Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947 [TBL] [Abstract][Full Text] [Related]
10. Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria. Hamman K; Clark H; Montini E; Al-Dhalimy M; Grompe M; Finegold M; Harding CO Mol Ther; 2005 Aug; 12(2):337-44. PubMed ID: 16043102 [TBL] [Abstract][Full Text] [Related]
11. A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. Erlandsen H; Stevens RC J Inherit Metab Dis; 2001 Apr; 24(2):213-30. PubMed ID: 11405341 [TBL] [Abstract][Full Text] [Related]
12. New protein structures provide an updated understanding of phenylketonuria. Jaffe EK Mol Genet Metab; 2017 Aug; 121(4):289-296. PubMed ID: 28645531 [TBL] [Abstract][Full Text] [Related]
13. Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase, and importance of genotypes for pharmacological therapy of phenylketonuria. Heintz C; Cotton RG; Blau N Hum Mutat; 2013 Jul; 34(7):927-36. PubMed ID: 23559577 [TBL] [Abstract][Full Text] [Related]
14. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU). Hamman KJ; Winn SR; Harding CO Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493 [TBL] [Abstract][Full Text] [Related]
16. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263 [TBL] [Abstract][Full Text] [Related]
17. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency. Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130 [TBL] [Abstract][Full Text] [Related]
18. The G46S-hPAH mutant protein: a model to study the rescue of aggregation-prone PKU mutations by chaperones. Leandro J; Saraste J; Leandro P; Flatmark T Mol Genet Metab; 2011; 104 Suppl():S40-4. PubMed ID: 21871828 [TBL] [Abstract][Full Text] [Related]
19. Mutational spectrum of the phenylalanine hydroxylase gene in patients with phenylketonuria in the central region of China. Zhang Z; Gao JJ; Feng Y; Zhu LL; Yan H; Shi XF; Chang AM; Shi Y; Wang P Scand J Clin Lab Invest; 2018 May; 78(3):211-218. PubMed ID: 29390883 [TBL] [Abstract][Full Text] [Related]